ERIN SIMANIC: Open Payments
NPI 1326594045 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,297 in 153 payments from 14 companies in 2025. Trend: 2023 $871 · 2024 $1,357 · 2025 $2,297
Food & beverage: $2,221Education: $76
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 28 | $398 |
| ABBVIE INC. | 30 | $325 |
| Teva Pharmaceuticals USA, Inc. | 17 | $283 |
| Lundbeck LLC | 10 | $250 |
| E.R. Squibb & Sons, L.L.C. | 23 | $213 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $178 |
| Neurocrine BioSciences, Inc. | 13 | $176 |
| Janssen Pharmaceuticals, Inc | 5 | $175 |
| Alkermes, Inc. | 6 | $107 |
| Axsome Therapeutics, Inc. | 4 | $64 |
Products named: REXULTI, VRAYLAR, COBENFY, UZEDY, CAPLYTA, INGREZZA, ABILIFY MAINTENA, SPRAVATO.
Industry payments across NE — which companies pay providers there.
